EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade ...

Sam S. Chang MD, MBA, discusses intravesical mitomycin in low-grade intermediate-risk nonmuscle-invasive bladder cancer vs ...

A mucoadhesive nanoplatform improves bladder cancer imaging by selectively targeting tumors and enhancing visualization for more precise non-invasive diagnosis.

People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour (TURBT). Mitomycin C (MMC) and Bacillus Calmette-Guérin ...

Tumor cells were CK20 +, CDX2 +, and CK7 −. The patient subsequently underwent an open bladder resection, which led to total excision of the neoplasm with clear resection margins.

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

TURBT was associated with persistent sexual dysfunction in men, pointing to the importance of incorporating sexual health into postoperative evaluation.

TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported ...

A breakthrough in bladder cancer treatment at the University of California, Davis: multifunctional nanoparticles enhance ...

Introduction Low anterior resection syndrome (LARS) is described as disordered bowel function after rectal resection that leads to a detriment in quality of life, and affects the majority of ...

Prostate and bladder cancer in men can be prevented with the right lifestyle practices. Around Father's Day 2025 is a good time to learn such tips. | Health ...